NCT03652077 - A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 24, 2018

Primary Completion Date

August 18, 2021

Study Completion Date

August 18, 2021

Conditions

Cervical CancerGastric CancerStomach CancerGastroesophageal Junction CancerEsophageal CancerHepatocellular CarcinomaMelanomaUveal MelanomaMerkel Cell CarcinomaMesotheliomaMSINon-small Cell Lung CancerNSCLCOvarian CancerSquamous Cell Carcinoma of the Head and NeckSmall Cell Lung CancerRenal Cell CarcinomaRCCTriple-negative Breast CancerUrothelial CarcinomaMismatch Repair Deficiency

Interventions

DRUG

INCAGN02390

Part 1: INCAGN02390 at the protocol-defined starting dose administered every 2 weeks (Q2W), with dose escalation in 7 total cohorts to determine the maximum tolerated dose or PAD.

Trial Locations (4)

28078

Carolina BioOncology, Huntsville

39216

University of Mississippi, Jackson

90025

The Angeles Clinical and Research Institute, Los Angeles

07601

Hackensack Medical Center, Hackensack